Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Everest Medicines Ltd. (HK:1952)

HKEX:1952

1952

Everest Medicines Ltd.

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding HK:1952?

Track your performance easily

Link Broker

Everest Medicines Ltd. (1952) Stock Price & Analysis

2 Followers

1952 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$14.34 - HK$37.15

Previous CloseHK$33.5

Volume7.29M

Average Volume (3M)3.63M

Market Cap

HK$10.90B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Mar 27, 2025

EPS Estimate

-HK$1.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.56

Shares OutstandingN/A

10 Day Avg. Volume7,028,399

30 Day Avg. Volume3,627,260

Standard Deviation0.30

R-Squared0.42

Alpha0.03

Financial Highlights & Ratios

Price to Book (P/B)0.00

Price to Sales (P/S)294.46

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$25.00

Price Target Upside-25.37% Downside

Rating ConsensusHold

Number of Analyst Covering1

Everest Medicines Ltd. News

PremiumCompany Announcements

Everest Medicines Expands NEFECON’s Reach in Asia

13d ago

1952

PremiumCompany Announcements

Everest Medicines Awards Stock Options to Talent

1M ago

1952

PremiumCompany Announcements

Everest Medicines Announces Mid-Year Financials

2M ago

1952

PremiumCompany Announcements

Everest Medicines Schedules Key Financial Review Meeting

3M ago

1952

PremiumCompany Announcements

Everest Medicines Shareholders Approve Key Resolutions

4M ago

1952

PremiumCompany Announcements

Everest Medicines Ltd. Prepares for AGM 2024

5M ago

1952

See More HK:1952 News >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.02% Mutual Funds

― Other Institutional Investors

96.92% Public Companies and

Individual Investors

Detailed Ownership Overview >

1952 FAQ

What was Everest Medicines Ltd.’s price range in the past 12 months?

Everest Medicines Ltd. lowest stock price was HK$14.34 and its highest was HK$37.15 in the past 12 months.

What is Everest Medicines Ltd.’s market cap?

Currently, no data Available

When is Everest Medicines Ltd.’s upcoming earnings report date?

Everest Medicines Ltd.’s upcoming earnings report date is Mar 27, 2025 which is in 142 days.

How were Everest Medicines Ltd.’s earnings last quarter?

Everest Medicines Ltd. released its earnings results on Aug 28, 2024. The company reported -HK$2.155 earnings per share for the quarter, missing the consensus estimate of -HK$1.105 by -HK$1.05.

Is Everest Medicines Ltd. overvalued?

According to Wall Street analysts Everest Medicines Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Everest Medicines Ltd. pay dividends?

Everest Medicines Ltd. does not currently pay dividends.

What is Everest Medicines Ltd.’s EPS estimate?

Everest Medicines Ltd.’s EPS estimate is -HK$1.16.

How many shares outstanding does Everest Medicines Ltd. have?

Everest Medicines Ltd. has 325,337,680 shares outstanding.

What happened to Everest Medicines Ltd.’s price movement after its last earnings report?

Everest Medicines Ltd. reported an EPS of -HK$2.155 in its last earnings report, missing expectations of -HK$1.105. Following the earnings report the stock price went down -0.238%.

Which hedge fund is a major shareholder of Everest Medicines Ltd.?

Currently, no hedge funds are holding shares in HK:1952

---

Everest Medicines Ltd. Stock Smart Score

Unlock Smart Score

Analyst Consensus

Hold

Average Price Target:
HK$25.00 (-25.37% Downside)

Technicals

Fundamentals

Return on Equity

-21.54%

Trailing 12-Months

Asset Growth

-12.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Everest Medicines Ltd.

Everest Medicines Ltd is a biopharmaceutical company that integrates licensing, clinical development, and commercialization of potentially globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company has assembled a portfolio of eight clinical-stage drug candidates for oncology, immunology, cardio-renal disease, and infectious disease.

---

1952 Stock 12 Month Forecast

Average Price Target

HK$25.00

▼(-25.37% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","30":"HK$30","14.25":"HK$14.25","19.5":"HK$19.5","24.75":"HK$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14.25,19.5,24.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.32,16.064615384615387,16.80923076923077,17.553846153846155,18.298461538461538,19.043076923076924,19.787692307692307,20.532307692307693,21.276923076923076,22.021538461538462,22.766153846153845,23.51076923076923,24.255384615384614,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.28,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.44,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.34,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.82,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.8,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.05,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.1,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.75,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.3,"date":1698969600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.05,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.96,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >